Shouyao Holdings Receives Approval for CT-3505 ALK Inhibitor Study in NSCLC
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced it has received ethical approval from...
InnoCare Pharma Doses First Patient in ICP-488 Study for Autoimmune Diseases
China-based InnoCare Pharma (HKG: 9969) announced that the first subject has been dosed in a...
Convalife Pharmaceuticals Licenses Karus Therapeutics’ CVL237 Globally
Shanghai-based Convalife Pharmaceuticals has entered into a licensing agreement with UK-based Karus Therapeutics Ltd, acquiring...
Unicycive Therapeutics Licenses Renazorb to Lee’s Pharma for Asian Markets
U.S.-based biotech Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced a licensing agreement with Hong Kong-listed Lee’s...
HutchMed Initiates China Bridging Study for Tazverik in Follicular Lymphoma
HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a bridging study for Tazverik (tazemetostat)...
Hainan Shuangcheng to Transfer Triptorelin Assets to Chongqing Lummy for USD 4.7M
Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) will transfer all tangible and intangible assets and...
Eccogene Receives FDA Approval for ECC4703 Phase I Study in NASH and Dyslipidemia
Shanghai-based biopharmaceutical company Eccogene announced it has received approval from the U.S. Food and Drug...
HutchMed’s H1 2022 Oncology Sales Surge 82% on Strong Product Performance
China-based biopharma HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) reported strong financial results for the...
Lion TCR Enrolls First Patient in LioCyx-M004 Study for HBV-Related Liver Cancer
Singapore-based clinical-stage biotech Lion TCR announced the enrollment of the first subject in a clinical...
Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review
Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has...
OriginCell Therapeutics Raises USD 120M in Series B for Tumor Immunotherapy Pipeline
OriginCell Therapeutics, a Shanghai-based tumor immunotherapy specialist, reportedly raised over USD 120 million in a...
Fosun Pharma to Hike Aitrox Stake to 72.63% for USD 61M
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) plans to increase its ownership...
GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline
GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly...
Ribo Life Science Raises USD 40M in Series E1 Round for siRNA Drug Development
China-based Suzhou Ribo Life Science Co., Ltd reportedly raised USD 40 million in a Series...
BridGene Biosciences Completes USD 38.5M Series B Round with China Funds
U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5...
Basecare Medical Sells 35% Stake in Cellpro Biotech for USD 9.5M
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based IVF specialist, will sell a 35%...
Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical...
Pica Partners with BrainCo to Launch ADHD Product in China
Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with...
NHC Designates National Mental Illness Medical Centers in Beijing and Shanghai
The National Healthcare Commission (NHC) announced the establishment of national mental illness medical centers, designating...
Innovent and Laekna Dose First Patient in Afuresertib and Tyvyt Study for PD-1 Resistant Tumors
China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that...